PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY, WITH SUBCUTANEOUS IMMUNOTHERAPY IN DEPOT PRESENTATION, IN PARALLEL GROUPS AND PLACEBO-CONTROLLED, IN PATIENTS WITH RHINOCONJUNCTIVITIS WITH OR WITHOUT ASTHMA SENSITIZED TO PARIETARIA JUDAICA

Trial Profile

PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY, WITH SUBCUTANEOUS IMMUNOTHERAPY IN DEPOT PRESENTATION, IN PARALLEL GROUPS AND PLACEBO-CONTROLLED, IN PATIENTS WITH RHINOCONJUNCTIVITIS WITH OR WITHOUT ASTHMA SENSITIZED TO PARIETARIA JUDAICA

Completed
Phase of Trial: Phase II

Latest Information Update: 06 May 2016

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary)
  • Indications Asthma; Grass pollen hypersensitivity
  • Focus Pharmacodynamics
  • Sponsors Bial
  • Most Recent Events

    • 06 May 2016 Status changed from recruiting to completed.
    • 28 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top